upper waypoint

23andMe Profits Off Big Pharma Demand for Genetic Data

at
Save ArticleSave Article
Failed to save article

Please try again

One of the themes of the current tech boom has been big data, which promises to change everything from business to government, to medicine. 23andMe is a startup that offers genetic tests for $99. Earlier this week 23andMe struck a deal with the drug company Pfizer, which is paying an undisclosed sum to get the genetic information of 5,000 people in 23andMe's database.

Sponsored

lower waypoint
next waypoint
California PUC Considers New Fixed Charge for ElectricityPro-Palestinian Protests on California College Campuses: What Are Students Demanding?Gaza War Ceasefire Talks Continue as Israel Threatens Rafah InvasionWill the U.S. Really Ban TikTok?Know Your Rights: California Protesters' Legal Standing Under the First AmendmentCalifornia Forever Shells out $2M in Campaign to Build City from ScratchSaying Goodbye to AsiaSF; New State Mushroom; Farm Workers Buy Mobile Home Park‘I’m Gonna Miss It’: Inside One of AsiaSF’s Last Live Cabarets in SoMaHow Wheelchair Rentals Can Open Up Bay Area Beaches (and Where to Find Them)California Housing Is Even Less Affordable Than You Think, UC Berkeley Study Says